A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings

Completed

• Conditions: Severe Alopecia Areata
• Interventions: Drug: Ritlecitinib

• Registration Number: NCT07200128
• Lead Sponsor: Pfizer

Brief Summary

This study is a secondary analysis of the Adelphi Real World Alopecia Areata II United States Disease Specific Programmes database. This database contains data from a cross-sectional study capturing linked physician and patient survey data for dermatologists who treat alopecia areata and patients diagnosed with alopecia areata in the United States. The retrospective analysis of these data will evaluate experiences of patients and dermatologists receiving/prescribing ritlecitinib for severe alopecia areata in the United States. Specifically, the study will describe characteristics of patients who received ritlecitinib for severe alopecia areata, including demographics, clinical characteristics at the time of starting ritlecitinib, and their alopecia areata-related treatment history. The study will also report dermatologist satisfaction with treatment and change in the patient's alopecia areata severity and disease activity from the start of ritlecitinib to different time points on treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-02-03
• Primary Completion: 2025-05-30
• Study Completion: 2025-05-30
• Status Verified: 2025-09
• Study First Submitted: 2025-09-22
• Study First Submitted QC: 2025-09-22
• Last Update Submitted: 2025-09-22
• Study First Posted: 2025-09-30
• Last Update Posted: 2025-09-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 123

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with severe Alopecia Areata	Ritlecitinib	-

Primary Outcome Measures

Name	Time	Method
% of patients for whom their clinician was "satisfied" with current control of alopecia areata	11/15/2023 to 06/10/2024
% of patients with clinician-assessed mild, moderate, or severe disease	11/15/2023 to 06/10/2024
% of patients with clinician assessed progressive, stable, or improving disease	11/15/2023 to 06/10/2024

Trial Locations

Locations (1)

Pfizer; 🇺🇸 New York, New York, United States